Kazia Therapeutics Newsroom

Kazia Therapeutics Analyst Ratings

BenzingaJul 12 06:41 ET

Buy Rating on Kazia Therapeutics Backed by Promising GBM Study Results and Strong Financial Valuation

TipRanksJul 12 06:19 ET

HC Wainwright & Co. Upgrades Kazia Therapeutics to Buy, Announces $2 Price Target

BenzingaApr 11, 2023 06:21 ET

Kazia Therapeutics Cut to Hold From Buy by Maxim Group

Dow JonesAug 2, 2022 08:53 ET

Analysts Offer Insights on Healthcare Companies: Kazia Therapeutics (KZIA), EyePoint Pharmaceuticals (EYPT) and Oramed Pharmaceuticals (ORMP)

TipRanksAug 2, 2022 06:20 ET

Kazia Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow JonesAug 2, 2022 06:17 ET

Kazia Therapeutics analyst ratings

Benzinga Analyst RatingsAug 2, 2022 06:11 ET

Kazia Therapeutics Price Target Cut 76% to A$0.45/Share by Bell Potter

Dow JonesAug 1, 2022 18:55 ET